S&P BSE Momentum Index Corporate Filings & Announcements

Latest corporate announcements and filings from S&P BSE Momentum Index on BSE

Search Inside the pdf :

Persistent Systems Ltd.

23 May 2025, 11:41PM

5662.00

1.42%

Company Update

Persistent Systems Ltd - 533179 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

The outcome of Investor/analyst session held on Friday, May 23, 2025, is as enclosed.

pdf

Torrent Pharmaceuticals Ltd.

23 May 2025, 10:34PM

3174.70

-1.16%

Earnings Call

Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of Conference Call

pdf

Glenmark Pharmaceuticals Ltd.

23 May 2025, 10:33PM

1420.20

-0.78%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Intimation Under Regulation 30 Of Securities And Exchange Board Of …

BSE India

We wish to inform you that a wholly owned subsidiary company of GPL in the name of "Glenmark Consumer Care Limited" has been incorporated on May 23, 2025.

pdf

Glenmark Pharmaceuticals Ltd.

23 May 2025, 09:24PM

1420.20

-0.78%

Investor Presentation

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Investor Presentation Q4, F.Y. 2024-25

pdf

United Spirits Ltd.

23 May 2025, 08:41PM

1578.90

0.67%

Company Update

United Spirits Ltd - 532432 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Investor call recording

pdf

United Spirits Ltd.

23 May 2025, 08:28PM

1578.90

0.67%

Company Update

United Spirits Ltd - 532432 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Schedule of Analysts/Institutional Investors meeting - Conference

pdf

Glenmark Pharmaceuticals Ltd.

23 May 2025, 08:10PM

1420.20

-0.78%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please find enclosed herewith Press Release and Management Discussion & Analysis for the Fourth Quarter and year ended March 31, 2025

pdf

Glenmark Pharmaceuticals Ltd.

23 May 2025, 07:52PM

1420.20

-0.78%

Corp. Action

Glenmark Pharmaceuticals Ltd - 532296 - Corporate Action-Board to consider Dividend

BSE India

The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares capital of the Company for the financial year 2024-25 subject to the approval of the Shareholders at the ensuing Annual General Meeting.

pdf

Glenmark Pharmaceuticals Ltd.

23 May 2025, 07:46PM

1420.20

-0.78%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Appointment of Mr. Anurag Mantri as an Additional Director (Whole-Time Director - Designated as Executive Director) and Global Chief Financial Officer of the Company

pdf

Glenmark Pharmaceuticals Ltd.

23 May 2025, 07:39PM

1420.20

-0.78%

Board Meeting

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Outcome for Audited Financial Results And Recommendation Of …

BSE India

The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on 23rd May, 2025, which commenced at 02.00 p.m. and concluded at 04:54 p.m., considered and approved the following: 1. Audited Financial Results for the quarter and year ended March 31, 2025. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com. 2. Recommended Dividend @ 250% i.e. Rs. 2.5/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2024-25 subject to the approval of the Shareholders at the ensuing Annual General Meeting.

pdf

S&P BSE Momentum Index PB	8.7
S&P BSE Momentum Index PE	42.4
S&P BSE Momentum Index DIV	0.9
S&P BSE Momentum Index EPS	49.9